Enigmas of P53 tumor suppressor gene

Experimental Oncology

Volumn 18, Issue 2, 1996, Pages 197-207

  Belousova, A K ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Apoptosis; Mutant protein; Protein p53; Suppressor gene

Indexed keywords

EID: 0039583081     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Lane DP, Crawford LV. T-antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-3.
2. Crawford LV, Pim DE, Gurney ED et al. Detection of a common feature in several human tumor cell lines - a 53000 dalton protein. Proc Nat Acad Sci USA 1981; 78: 41-5.
3. Baker SJ, Fearon ER, Nigro JM et al. Chromosome 17 deletions and p53 mutations in colorectal carcinoma. Science 1989; 299: 217-21.
4. Lothe RO, Fossel T, Danielson E et al. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumor J Nat Cancer Inst 1992; 84: 1100-8.
5. Levin AJ, Momand Y, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
6. Blum E. p53: How a tumor suppressor works. J Nat Cancer Inst 1991; 83: 156-8.
7. Erlich HA, Gelfand D, Sninsky JJ. Recent advances in the polymerase chain reaction. Science 1991; 252: 1643-51.
8. Lane DP. Cancer. p53, guardian of the genome. Nature 1991; 358: 15-6.
9. Freiberg T, Friend SH. The importance of p53 alterations in human cancer, is there more than circumstantial evidence J Nat Cancer Inst 1993; 85: 1554-7.
10. Callahan R. p53 mutations, another breast cancer prognostic factor. J Nat Cancer Inst 1992; 84: 826-7.
11. Thor A, Moore DHI, Adgerstan SM et al. Accumulation of p53 tumor suppressor gene protein an independent marker of prognosis in breast cancer. J Nat Cancer Inst 1992; 84: 845-55.
12. Jsola Y, Visacorpi T, Holli O-P, Callionemi O-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Nat Cancer Inst 1992; 84: 1109-14.
13. Li F, Fraumeni J, Jr. Soft-tissue sarcomas, breast cancer and other neoplasms: a familial syndrome. Ann Int. Med 1969; 71: 747-53.
14. Srivastava S, Zou Z, Pirello K et al. Germ-line transmission of mutanted p53 gene in a cancer prone family with Li-Fraumeni syndrome. Nature 1990; 243: 747-9.
15. Kohler ME, Marks JR, Wiseman RW et al. Spectrum of mutations and frequency of allelic deletions of p53 gene in ovarian cancer. J Nat Cancer Inst 1993; 85: 1513-9.
16. Meyers F, Chi S-G, Fishman JR et al. p53 mutations in benign prostate hyperplasia. J Nat Cancer Inst 1993; 85: 1850-8.
17. Visacorpi TV, Kallionemi O-P, Heikkinen A et al. Small subgroup of aggressive, highly proliferative prostate carcinoma as defined by p53 accumulation. J Nat Cancer Inst 1992; 84: 883-7.
18. Navone NM Troncoso P, Pistores LL et al. p53 protein accumulation and gene mutations in the progression of human prostatic carcinoma. J Nat Cancer Inst 1993; 85: 1657-69.
19. Kim J-H, Takahashi T, Chiba L et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Nat Cancer Inst 1991; 83: 938-43.
20. Oliner JD, Kinzler KW, Meltzer PS et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1990; 358, 80-3.
21. Meltzer PS. MDM2 and p53: a question of balance. J Nat Cancer Inst 1994; 86: 1265-6.
22. Florenes VA, Moclandsmo GM, Fores A et al. MDM2 gene amplification and transcription levels in human sarcomas: relationship to p53 gene status. J Nat Cancer Inst 1994, 86: 1297-302.
23. Zambetti GP, Levin A. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993; 7: 855-63.
24. Lianes P, Orlov Z, Zhang Z et al. Altered patterns of MDM2 and p53 expression in human bladder cancer. J Nat Cancer Inst 1994; 86: 1325-30.
25. Habushi T, Kikoshita H, Yamada M et al. Oncogene amplification in urothelial cancers with p53 mutations or MDM2 amplification. J Nat Cancer Inst 1994; 86: 1331-5.
26. Hartwell LH, Weinert TA. Checkpoints: control that ensures the order of cell cycle events. Science 1989; 246: 629-34.
27. Pritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307-18.
28. Kastan MB, Oniekwere O, Sitransky D et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
29. Bowersox J. Research gain insight into cellular delay. J Nat Cancer Inst 1992; 84: 1859-60.
30. Kurbitz SJ, Plunkett BS, Wash WV et al. Wild type p53 is a cellular checkpoint determinant following irradiation. Proc Nat Acad Sci USA 1992; 89: 7491-5.
31. 1 phase. Proc Nat Acad Sci USA 1992; 89: 9210-4.
32. Kern S, Kinzler KW, Briskin A et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252: 1708-11.
33. Farmer G, Barganetti J, Xhu H et al. Wild-type p53 activates transcription in vitro. Nature 1992; 358: 83-6.
34. Fields S, Jung SK. Presence of a potent transcription activity sequence in the p53 protein. Science 1990; 249: 1046-9.
35. Reicroft L, Wu HY, Lozano G. Transcriptional activation by wild-type but not transforming mutant of the p53 antioncogene. Science 1990; 249: 1049-51.
36. Chin K-W, Ueda Z, Pastan I, Gottesman M. Modulation activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-62.
37. Seto E, Usheva A, Zambellig P et al. Wildtype p53 binds to the TATA-binding protein and represses transcription. Proc Nat Acad Sci USA 1992; 89: 12028-32.
38. Mack DH, Varticar J, Pipas JM et al. Specific suppression of TATA-mediated but not initiator-mediated transcription by the wild-type p53. Nature 1993; 366: 281-3.
39. Vogelstein B, Kenzler KW. X-ray strike p53 again. Nature 1994; 370: 174-5.
40. Bischoff JR, Friedman FW, Marshak DK et al. Human p53 is phosphorylated by p60-cdc2 and cyclinB-cdc2. Proc Nat Acad Sci USA 1990; 87: 4766-70.
41. Girard F, Strausfeild U, Fernandez A, Lamb N. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991; 67: 1169-79.
42. cdc2. Cell 1989; 53: 839-40.
43. Hunter T, Pines J. Cyclines and cancer. Cell 1991; 66: 1074-9.
44. 1 cyclin (Cln) function in yeast. Cell 1991; 66: 1197-206.
45. 1, a new cyclin that interacts with the members of cdc2 family. Cell 1991; 66: 1217-28.
46. Draetta G, Piwnica-Warms H, Morrison D et al. Human cdc2 protein kinase is a major cell-cycle regulated thyrosine kinase substrate. Nature 1988; 336: 738-44.
47. El-Deiry VS, Tokino T, Velculesku VE et al. WAF-I, a potent mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
48. 1 arrest. Cell 1994; 76: 1013-23.
49. Xiong Y, Hannon G, Zhang H et al. p21 is universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
50. Waga S, Stillman B. Anatomy of a DNA replication fork revealed by reconstitution of SV40 DNA replication in vitro. Nature 1994; 369: 207-12.
51. Cleaver JE. It was a very good year for DNA repair. Cell 1994; 76: 1-4.
52. Li R, Waga S, Kannon G et al. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371: 534-7.
53. O'Connor RU, Ferri DK, White GA et al. Relationship between cdc2 kinase, DNA cross-linking, and cell-cycle perturbations induced by nitrogen mustard. Cell Growth Differ 1992; 3: 43-52.
54. cdc2. Cell 1992; 68: 787-97.
55. Galaktionov K, Beach D. Specific activation of cdc25 thyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 1991; 67: 1181-94.
56. Nabori T, Miure K, Wu DJ et al. Deletions of the cyclin-dependent kinase 4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
57. Stewart BW. Mechanism of apoptosis: integration genetic, biochemical and cellular indicators. J Nat Cancer Inst 1994; 86: 1286-96.
58. Vaux DL, Haeckern G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994; 76: 777-9.
59. Caellis C, Helmberg A, Korin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target gene. Nature 1994; 370: 220-3.
60. Hensel JW, Wesselschmidt RL, Shresta S et al. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogenic target cells. Cell 1994; 76: 977-87.
61. Morgenbesser SD, Williams BO, Jacks T, Pinko D. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994; 371:72-4.
62. White E. p53, guardian of Rb. Nature 1994; 371: 21-2.